Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Regorafenib Post-marketing Surveillance in Japan

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by Bayer
Information provided by (Responsible Party):
Bayer Identifier:
First received: August 29, 2013
Last updated: May 17, 2017
Last verified: May 2017
The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Condition Intervention
Gastrointestinal Stromal Tumors
Drug: Regorafenib (Stivarga, BAY73-4506)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Drug Use Investigation of Regorafenib/ STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib. [ Time Frame: Up to 6 months ]
  • Number of patients with serious adverse events(SAEs) from the first administration of regorafenib. [ Time Frame: Up to 6 months ]
  • Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib [ Time Frame: up to 6 months ]

Secondary Outcome Measures:
  • overall survival (OS) [ Time Frame: Up to 3 years ]
  • time to treatment failure (TTF) [ Time Frame: Up to 3 years ]
    TTF is defined as the time interval from start of Regorafenib/ STIVARGA therapy to the date of permanent discontinuation for any reason including disease progression, adverse event, patient preference or death.

  • tumour response [ Time Frame: Up to 3 years ]
  • Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor. [ Time Frame: Up to 3 years ]
    Integration analysis including incidence and risk factor of adverse drug reaction (ADR), serious adverse event (SAE) and serious adverse drug reaction (SADR)

Estimated Enrollment: 135
Actual Study Start Date: September 4, 2013
Estimated Study Completion Date: June 25, 2021
Estimated Primary Completion Date: June 25, 2021 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
Drug: Regorafenib (Stivarga, BAY73-4506)
The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.

Detailed Description:

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy.

A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who are treated with Regorafenib/STIVARGA and meet the product label

Inclusion Criteria:

  • Patients who are treated with Regorafenib/ STIVARGA and meet the product label.

Exclusion Criteria:

  • Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01933958

Contact: Bayer Clinical Trials Contact 49 30 300139003

Many Locations, Japan
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bayer Identifier: NCT01933958     History of Changes
Other Study ID Numbers: 16732
STIVARGA-GIST-01 ( Other Identifier: company internal )
Study First Received: August 29, 2013
Last Updated: May 17, 2017

Keywords provided by Bayer:
Gastrointestinal stromal tumors

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases processed this record on May 25, 2017